068760.KQ KOE
Celltrion Pharm, Inc.
1W: -1.7%
1M: -7.6%
3M: -7.0%
YTD: -45.4%
1Y: -27.4%
3Y: -52.5%
5Y: -70.9%
₩38,400.00 ($28.59)
-1250.00 (-3.15%)
Weekly Expected Move ±3.4%
₩35808
₩37104
₩38400
₩39696
₩40992
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$759.4B
+13.4% ▲
5Y CAGR: +6.7%
Total Liabilities
$323.5B
+18.7% ▲
5Y CAGR: +5.5%
Shareholders Equity
$436.0B
+9.8% ▲
5Y CAGR: +7.7%
Cash & Investments
$116.9B
+68.0% ▲
5Y CAGR: +31.5%
Total Debt
$177.9B
+3.3% ▲
5Y CAGR: -1.6%
Net Debt
$128.0B
+1.0% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $80.2B | $31.4B | $19.7B | $45.5B | $49.9B |
| Short-Term Investments | $8.0B | $17.7B | $17.4B | $24.1B | $67.1B |
| Cash & ST Investments | $88.2B | $49.1B | $37.1B | $69.6B | $116.9B |
| Net Receivables | $174.0B | $187.6B | $222.5B | $218.5B | $225.6B |
| Inventory | $63.9B | $69.2B | $100.4B | $101.4B | $122.9B |
| Other Current Assets | $0 | $0 | $0 | -$1K | $0 |
| Total Current Assets | $331.1B | $311.9B | $364.8B | $391.7B | $470.6B |
| Property, Plant & Equip. | $241.9B | $228.2B | $220.8B | $222.7B | $220.8B |
| Goodwill & Intangibles | $39.4B | $41.3B | $39.3B | $39.2B | $43.2B |
| Long-Term Investments | $2.1B | $1.6B | $1.5B | -$23.9B | $1.7B |
| Other Non-Current Assets | $10.1B | $4.1B | $4.5B | $30.5B | $12.9B |
| Total Non-Current Assets | $306.7B | $287.8B | $276.8B | $277.8B | $288.8B |
| Total Assets | $637.9B | $599.7B | $641.6B | $669.5B | $759.4B |
| — Liabilities — | |||||
| Accounts Payable | $72.6B | $38.1B | $59.3B | $46.7B | $78.7B |
| Short-Term Debt | $141.1B | $138.6B | $153.8B | $154.9B | $144.8B |
| Deferred Revenue | $13.4B | $521M | $567M | $0 | $1.2B |
| Other Current Liabilities | $5.7B | $4.9B | $7.0B | $5.9B | $52.6B |
| Total Current Liabilities | $259.9B | $212.0B | $249.3B | $247.7B | $283.6B |
| Long-Term Debt | $39.0B | $21.7B | $4.3B | $0 | $16.6B |
| Other Non-Current Liab. | $979M | $885M | $1.1B | $1.5B | -$3.6B |
| Total Non-Current Liabilities | $43.0B | $30.9B | $15.6B | $24.9B | $39.9B |
| Total Liabilities | $302.9B | $242.9B | $265.0B | $272.5B | $323.5B |
| — Equity — | |||||
| Common Stock | $18.3B | $18.9B | $19.8B | $20.8B | $21.8B |
| Retained Earnings | $65.7B | $91.1B | $111.4B | $132.4B | $170.1B |
| Accumulated OCI | $3.3B | $5.5B | $7.6B | $9.6B | $11.9B |
| Total Stockholders Equity | $332.0B | $356.8B | $376.7B | $396.9B | $436.0B |
| Total Liabilities & Equity | $637.9B | $599.7B | $641.6B | $669.5B | $759.4B |
| — Key Metrics — | |||||
| Total Debt | $181.0B | $160.7B | $162.5B | $172.2B | $177.9B |
| Net Debt | $100.8B | $129.3B | $142.8B | $126.7B | $128.0B |
| Total Investments | $10.1B | $19.3B | $18.9B | $230M | $68.7B |